Drug intelligence / Profile preview

18F-FD4

Development stage: Preclinical
Lead developer: SynuSight Biotech
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-FD4 is a radiopharmaceutical tracer labeled with Fluorine-18 (18F) developed for use in Positron Emission Tomography (PET) imaging. Its primary application is to detect and visualize alpha-synuclein aggregates in the brain, a key pathological hallmark of neurodegenerative disorders such as Parkinson's disease and multiple system atrophy. The tracer is administered via injection and is currently being investigated in clinical studies by institutions including Huashan Hospital, Fudan University, and the National Natural Science Foundation of China.

Targets

α-syn fibril (Alpha-synuclein (SNCA))

Beyond the preview

Go deeper on 18F-FD4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-FD4.

Explore the full profile